Hearing loss is the most common sensory disorder, affecting hundreds of millions of people globally. A substantial proportion of cases are genetic in origin. More than 250 genes and hundreds of thousands of pathogenic variants have been implicated in both nonsyndromic and common syndromic forms of hearing loss. This extensive genetic diversity contributes to substantial variability in age of onset, severity, progression, and audiometric patterns, making phenotype alone insufficient to fully determine etiology or predict clinical course.
Genetic testing is increasingly recognized as a standard component of care for individuals with hearing loss. It enables efficient identification of underlying molecular causes across diverse clinical presentations. Establishing a molecular diagnosis can improve prognosis, clarify the risk of progression, guide surveillance for syndromic features, and inform management and treatment. Molecular findings also provide a clearer framework for discussing recurrence risk and long-term expectations with patients and families. Emerging therapeutic approaches, including gene replacement trials for OTOF-related hearing loss, further illustrate how genetic insights are informing the development of targeted therapies.
As genomic knowledge expands, molecular diagnosis is becoming increasingly critical to understanding and managing hearing loss and contributing to a more precise, mechanism-informed approach to audiologic care.
Learning Objectives:
- Describe the genetic architecture and heterogeneity of hearing loss and how it contributes to variability in clinical presentation.
- Explain the possible outcomes of genetic testing for hearing loss (diagnostic findings, variants of uncertain significance, and negative results).
- Discuss how molecular diagnosis can inform prognosis, risk of progression, management, and surveillance for syndromic features.
- Discuss the evolving role of genetic information in clinical hearing care, including implications for emerging gene-based therapies.
